⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
18,427
Total Claims
$8.9M
Drug Cost
1,047
Beneficiaries
$8,541
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+117%
Cost per patient vs peers
$8,541 vs $3,933 avg
+9%
Brand preference vs peers
55.9% vs 51.2% avg
Brand vs Generic
44% generic
Brand: 9,439 claims · $8.7M
Generic: 7,450 claims · $183K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 2,416 | $2.7M |
| Tirzepatide | 1,230 | $1.5M |
| Empagliflozin/Metformin Hcl | 1,308 | $957K |
| Insulin Aspart Prot/Insuln Asp | 457 | $500K |
| Semaglutide | 412 | $473K |
| Empagliflozin | 474 | $394K |
| Insulin Regular, Human | 440 | $365K |
| Denosumab | 157 | $271K |
| Dapaglifloz Propaned/Metformin | 318 | $231K |
| Insulin Lispro Protamin/Lispro | 170 | $170K |
| Dapagliflozin Propanediol | 161 | $123K |
| Romosozumab-Aqqg | 34 | $84K |
| Icosapent Ethyl | 206 | $81K |
| Insulin Aspart | 100 | $75K |
| Evolocumab | 100 | $68K |
Prescribing Profile
Patient Profile
74
Avg Age
63%
Female
1.84
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About